- Price
- $66.48
- Day
- -1.86%
- Mkt Cap
- $9.36B
- 52W Range
- $30.71 – $95.49
- Volume
- 4.02M
- Beta
- 1.28
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.
Read full article
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Get ARWR alerts:Sign UpEarly Dimer Data Points to Dual-Target Approach Chief Executive Officer Chris Anzalone said the company's ARO-DIMER-PA candidate represented the first demonstration of knockdown of two genes with a single RNAi molecule.
Read full article
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Read full article
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC.
Read full article
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's
Read full article
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Read full article
The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by 9%.
Read full article
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type: Fireside Chat Presentation Date/Time: September 10, 2026, 10:55 am EDT Morgan Stanley 24th Annual Global Healthcare Conference – September 14-16, 2026 Type: Fireside Chat Presentation Date/Time: September 15, 2026, 11:30 am EDT H.C. Wainwright 28th Ann.
Read full article
Benjamin Edwards Inc. purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,841 shares of the biotechnology company's stock, valued at approximately $721,000. Several other hedge funds and other institutional
Read full article
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript
Read full article
Arrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data were presented at the European Society of Cardiology Congress in Munich and have been accepted for publication in a major medical journal.
Read full article